VICL (Vical Labs) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VICL (Vical Labs)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: A.J. Mullen	9/22/2010 10:16:41 AM
	Read Replies (1) of 1972

Vical shares crushed by failed drug trialRelated stories SNY BOSTON (MarketWatch) -- Shares of biotech group Vical Inc. /quotes/comstock/15!vicl (VICL 2.47, -1.39, -36.03%) were battered in early trading Wednesday on news that a Phase III clinical trial had shown its drug NV1FGF to be ineffective. French drug maker Sanofi-Aventis /quotes/comstock/13!sny/quotes/nls/sny (SNY 33.78, +0.44, +1.32%) , which licensed the product from Vical a few years ago, had been testing the drug to see if it could help patients with severe cardiovascular obstructions in their limbs avoid major amputations. Shares of Vical plunged 40% to $2.30, while Sanofi shares were up 1%. marketwatch.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next